Targeting Skin pH: A Novel Topical Approach for Atopic Dermatitis
Day 1 Supply & Formulation Excellence Stage
06/10/2026 14:15pm - 14:40pm
Contributors
Michael J Cork : Professor of Dermatology - Hyphens Pharma Pte Ltd
See Wah Lim : CEO - Hyphens Pharma Pte Ltd
Amid the rapid global rise of atopic dermatitis (AD), significant unmet needs remain in mild-to-moderate disease—particularly in safe, non-steroidal options that address underlying skin barrier dysfunction. In this session, Professor Michael Cork, a world-leading authority on skin pH in AD, will present compelling scientific evidence on the central role of skin pH as the master key in skin barrier homeostasis and inflammation.
His talk will highlight how targeted acidification can restore barrier integrity, rebalance the microbiome, and reduce disease severity. Building on this, Mr. See Wah Lim will introduce Cerapro® MED - the first MDR-approved Class IIa medical device for AD treatment with a patented technology that sustainably lowers skin pH over 12 hours while enhancing the skin’s inherent antimicrobial defense system. This session offers a differentiated, commercially attractive opportunity for partners seeking innovation in the evolving topical AD treatment category.